azacitidine has been researched along with glycine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 10 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Martin, DW; Owen, NT | 1 |
| Albrecht, S; Berthold, F; Goodyer, CG; Koch, A; Meyer-Puttlitz, B; Pietsch, T; Sörensen, N; Tonn, JC; Waha, A; Weggen, S; Wiestler, OD | 1 |
| Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
| List, AF | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Al-Kali, A; Atallah, E; Azarnia, N; Baer, MR; Collins, R; Fenaux, P; Gaidano, G; Garcia-Manero, G; Godley, LA; Greenberg, P; Jabbour, E; Kambhampati, S; Kantarjian, H; Kreuzer, KA; Platzbecker, U; Roboz, GJ; Scott, BL; Sekeres, MA; Silverman, LR; Steensma, DP; Wilhelm, FE | 1 |
| Navada, SC; Silverman, LR | 1 |
| Allen, JE; Babar, J; Benes, CH; Claxton, DF; Dicker, DT; El-Deiry, WS; Garnett, MJ; Grupp, SA; Hall, J; Khan, N; Kline, CLB; Lulla, AR; McDermott, U; Oster, W; Prabhu, VV; Pu, JJ; Talekar, MK; Van den Heuvel, APJ; Zhou, L | 1 |
| Azarnia, N; Fenaux, P; Fruchtman, SM; Garcia-Manero, G; Kantarjian, H; Komrokji, R; Nazha, A; Platzbecker, U; Prebet, T; Roboz, G; Santini, V; Sekeres, MA; Silverman, LR; Steensma, DP; Zbyszewski, PS | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Alvarado, Y; Demakos, EP; Fruchtman, SM; Garcia-Manero, G; John, RB; Maniar, M; Navada, SC; OdchimarReissig, R; Ohanian, MN; Pemmaraju, N; Silverman, LR; Woodman, RC; Zbyszewski, PS | 1 |
| Curcio, T; Desai, P; Edirisinghe, B; Lee, S; Pianello, S; Ritchie, EK; Roboz, GJ; Samuel, M | 1 |
| Choe, S; Daigle, S; de Botton, S; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Frankfurt, O; Franovic, A; Frattini, MG; Gianolio, DA; Goldwasser, M; Gong, J; Kantarjian, HM; Lersch, F; Martinelli, G; Patel, PA; Raffoux, E; Schuh, AC; Stein, AS; Stein, EM; Stone, RM; Tan, P; Vyas, P; Winkler, T; Wu, B; Zeidan, AM; Zhang, V | 1 |
| Bertani, G; Calado, RT; Daigle, SR; de Botton, S; Döhner, H; Gianolio, DA; Heuser, M; Hui, J; Montesinos, P; Pandya, SS; Recher, C; Schuh, AC; Vives, S; Wang, J; Yeh, SP; Zarzycka, E | 1 |
| Briceño-Casado, MP; Gil-Sierra, MD; Sierra-Sanchez, JF | 1 |
| Goodman, AM; Mohyuddin, GR; Prasad, V | 1 |
| de Botton, S; Döhner, H; Montesinos, P | 1 |
| Takahashi, K | 1 |
4 review(s) available for azacitidine and glycine
| Article | Year |
|---|---|
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydroxamic Acids; Lenalidomide; Myelodysplastic Syndromes; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Sequence Deletion; Sulfones; Thalidomide; Transforming Growth Factor beta; Tumor Microenvironment | 2012 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndromes; Prognosis; Sulfones; Survival Rate; Treatment Outcome | 2016 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
7 trial(s) available for azacitidine and glycine
| Article | Year |
|---|---|
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Europe; Female; Glycine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Sulfones; Treatment Outcome | 2016 |
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Drug Resistance, Neoplasm; Glycine; Humans; Kaplan-Meier Estimate; Myelodysplastic Syndromes; Prognosis; Sulfones; Treatment Outcome | 2017 |
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sulfones | 2020 |
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.
Topics: Azacitidine; DNA Methylation; Glycine; Humans; Hydroxamic Acids; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyridines | 2021 |
Ivosidenib and Azacitidine in
Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukopenia; Pyridines; Recurrence | 2022 |
9 other study(ies) available for azacitidine and glycine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Repression and derepression of purine biosynthesis in mammalian hepatoma cells in culture.
Topics: Acyltransferases; Adenine; Animals; Azacitidine; Carbon Isotopes; Carcinoma, Hepatocellular; Clone Cells; Cycloheximide; Dactinomycin; Feedback; Formates; Glycine; Kinetics; Ligases; Liver Neoplasms; Neoplasms, Experimental; Pentosephosphates; Pentosyltransferases; Purines; Rats; Ribonucleotides; Ribose; Tetrahydrofolates; Tritium | 1972 |
Epigenetic silencing of the HIC-1 gene in human medulloblastomas.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Northern; Cerebellar Neoplasms; Child; Child, Preschool; Cystine; Decitabine; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glycine; Humans; Infant; Loss of Heterozygosity; Male; Medulloblastoma; Methylation; Middle Aged; Molecular Sequence Data; Myogenic Regulatory Factors; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; RNA, Messenger; Sulfites; Tumor Cells, Cultured | 2003 |
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glycine; Hematologic Neoplasms; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mice; Mice, SCID; Pyridines; Pyrimidines; Transcription Factor CHOP; Transplantation, Heterologous | 2018 |
Ivosidenib Boosts OS with Azacitidine in AML.
Topics: Azacitidine; Glycine; Humans; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines | 2023 |